Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Participants With Influenza
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 600
- Registration Number
- NCT06094010
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Harrisburg Family Medical Center, Harrisburg, Arkansas, United States
🇺🇸Avanza Medical Research Center, Pensacola, Florida, United States
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 182
- Registration Number
- NCT06084936
- Locations
- 🇫🇷
CHU NANTES - Hôtel Dieu, Nantes, France
🇧🇷ICTR Curitiba, Curitiba, Paraná, Brazil
🇨🇳Chongqing Cancer Hospital, Chongqing, China
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
- Conditions
- Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Interventions
- Drug: LHRH AgonistDiagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
- First Posted Date
- 2023-10-04
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1050
- Registration Number
- NCT06065748
- Locations
- 🇨🇱
Clínica Puerto Montt, Puerto Montt, Chile
🇵🇪Oncosalud Sac, Lima, Peru
🇩🇪St. Elisabeth Krankenhaus Köln GmbH, Koeln, Germany
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2023-09-26
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 316
- Registration Number
- NCT06055075
- Locations
- 🇦🇺
Princess Alexandra Hospital Woolloongabba, Woolloongabba, Queensland, Australia
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇨🇦Hamilton Health Sciences, Hamilton, Ontario, Canada
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
- Conditions
- Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1130
- Registration Number
- NCT06047080
- Locations
- 🇺🇸
Alaska Oncology & Hematology, LLC, Anchorage, Alaska, United States
🇺🇸Kaiser Permanente - Anaheim (E. La Palma), Anaheim, California, United States
🇺🇸University of California, San Francisco-Fresno, Clovis, California, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of RO7589831 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-05-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 295
- Registration Number
- NCT06004245
- Locations
- 🇧🇪
UZ Leuven Gasthuisberg, Leuven, Belgium
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-05-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT05987449
- Locations
- 🇺🇸
UC Davis Cancer Center, Sacramento, California, United States
🇺🇸Georgetown Uni Medical Center, Washington, District of Columbia, United States
🇳🇿Auckland Cancer Trial Centre, Auckland, New Zealand
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye Disease
- Conditions
- Thyroid Eye DiseaseTED
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 131
- Registration Number
- NCT05987423
- Locations
- 🇩🇪
Charité-Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany
🇦🇹Medizinische Universität Wien, Wien, Austria
🇺🇸Thrive Health Research LLC, Beverly Hills, California, United States
A Study to Evaluate the Effectiveness and Safety of Polatuzumab in Real World Clinical Practice Among Adult Chinese Participants With Diffuse Large B-Cell Lymphoma
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1000
- Registration Number
- NCT05954910
- Locations
- 🇨🇳
Xinjiang Medical University Cancer Hospital, Urumqi City, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China
🇨🇳Wuxi People's Hospital, Wuxi, China
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Device: MS Care Platform (icobrain ms and icompanion ms)
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 500
- Registration Number
- NCT05949580
- Locations
- 🇩🇪
Universitaetsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany
🇩🇪Praxis Dr. med. Max Deist und Michael Ernst ?Sinsheim, Sinsheim, Germany